Clinical Variants of Acne & Treatment of Severe Acne Vulgaris

(10-Mark Format | 3rd Year Dermatology PG Theory Examination)

PART A: CLINICAL VARIANTS OF ACNE

1. Neonatal Acne / Neonatal Cephalic Pustulosis

• Occurs in >20% of healthy newborns within the first 4 weeks of life
• Characterized by papules and pustules predominantly on the cheeks and forehead
• Pathogenesis: colonization by Malassezia species (especially M. sympodialis, M. globosa), not C. acnes; the term "neonatal cephalic pustulosis" is now preferred
• Unlike infantile acne, it lacks comedones
• Management: Usually resolves spontaneously; topical antifungals (e.g., ketoconazole) may be used

2. Infantile Acne

• Onset between 3–6 months to 2 years of age
• Comedones, papules, pustules, and occasionally nodules on the face
• Elevated LH-stimulated testosterone (males) or adrenal DHEAS is implicated
• May be severe and leave permanent scarring
• Management: Topical retinoids, benzoyl peroxide; oral erythromycin (tetracyclines avoided <8 years); oral isotretinoin for severe cases
• Warrants workup for precocious puberty, congenital adrenal hyperplasia, or virilizing tumor

3. Preadolescent / Mid-Childhood Acne (7–11 years)

• Driven by adrenarche: rising DHEAS → increased sebum production
• Predominantly comedonal over the T-zone
• Evaluation for underlying endocrine disorders if severe

4. Post-Adolescent Acne in Women

• Inflammatory acne beyond 25 years; most common in women (35% in their 30s)
• Two patterns:
  • Diffuse pattern: Mixed inflammatory + comedonal lesions across face and trunk, similar to adolescent acne
  • Mandibular/U-zone pattern: Inflammatory papules, pustules, nodules confined exclusively to the lower face/jaw — strongly linked to hormonal fluctuations
• Premenstrual flares common (~44%)
• Up to 30% with irregular menses have signs of hyperandrogenism (PCOS, hirsutism, androgenetic alopecia)
• A comedonal adult-onset form associated with smoking exists
• Management: Combined OCPs, spironolactone, isotretinoin

5. Acne Fulminans (Acne Maligna) ★ Most Severe Form

• Affects adolescent boys (13–16 years) almost exclusively
• Sudden, explosive onset of painful, oozing, friable hemorrhagic plaques from pre-existing mild acne
• Systemic manifestations: High fever, severe malaise, arthralgias, myalgias, hepatosplenomegaly
• Bone lesions: Osteolytic lesions of clavicle, sternum, ankle, humerus (SAPHO association)
• Labs: Elevated ESR, leukocytosis, anemia, proteinuria
• Associated with: Late-onset congenital adrenal hyperplasia, anabolic steroid use, therapeutic testosterone
• Leaves severe scarring
• Treatment: See Part B

6. Acne Conglobata

• Severe form of nodulocystic acne — eruptive onset without systemic features (distinguishes it from acne fulminans)
• Deep interconnecting nodules and cysts, polyporus comedones, sinus tracts, pronounced scarring
• Predominantly affects the face, chest, back, buttocks, upper arms
• Part of the Follicular Occlusion Tetrad: Acne conglobata + dissecting cellulitis of scalp + hidradenitis suppurativa + pilonidal sinus
• Associated with PAPA syndrome (Pyogenic sterile Arthritis, Pyoderma gangrenosum, Acne conglobata) — AD, PSTPIP1 mutations
• Also seen in PAPASH and PASH syndromes
• Management: Oral isotretinoin is drug of choice; initial prednisone cover if very acute

7. Solid Facial Edema (Morbihan Disease)

• Unusual complication of acne vulgaris
• Woody, non-pitting induration of the midface and cheeks with erythema
• Caused by impaired lymphatic drainage and fibrosis from chronic inflammation
• Does not resolve spontaneously
• Treatment: Isotretinoin 0.2–1 mg/kg/day for 9–24 months; combination with ketotifen or prednisone may add benefit

8. Occupational Acne

• Due to workplace exposure to insoluble follicle-occluding substances
• Agents: Cutting oils, petroleum products, chlorinated aromatic hydrocarbons, coal tar derivatives
• Lesions in exposed and covered areas; comedones predominate
• Chloracne (MADISH): Caused by halogenated aromatic hydrocarbons (PCBs, dioxins); comedo-like lesions + yellowish cysts at malar/retro-auricular areas, axillae, scrotum; may persist for years

9. Acne Cosmetica and Pomade Acne

• Acne cosmetica: Predominantly closed comedones from follicle-occluding cosmetics
• Pomade acne: Comedones at the forehead and temples from oily hair products
• Maskne (Maske): Face mask-induced acneiform eruptions (increased during COVID-19 pandemic)

10. Acne Mechanica

• Caused by repetitive friction/pressure obstructing the pilosebaceous unit
• Triggers: Helmets, chin straps, collars, bra straps, crutches, prosthetic limbs
• Classic example: Fiddler's neck — comedones in a linear, lichenified plaque at the lateral neck from violin positioning
• Geometrically distributed comedones and papulopustules

11. Drug-Induced Acneiform Eruptions

• Monomorphous follicular pustules (no comedones — key differentiator)
• Common offenders:
  • Corticosteroids (steroid acne — truncal, uniform papulopustules)
  • EGFR inhibitors (erlotinib, cetuximab)
  • MEK inhibitors, anti-PD-1/PD-L1, CTLA-4 inhibitors
  • Halogens: Iodides (iododerma), bromides, lithium
  • Isoniazid, phenytoin, ciclosporin
  • JAK inhibitors: Upadacitinib, tofacitinib → exacerbate acne
  • BRAF inhibitors (vemurafenib): Comedo-like and cystic lesions resembling chloracne

12. Gram-Negative Folliculitis

• Complication of prolonged oral antibiotic therapy for acne
• Two types:
  • Type I (superficial): Perifollicular papulopustules around nose — Klebsiella, Enterobacter, Escherichia coli
  • Type II (deep): Nodulocystic — Proteus mirabilis
• Treatment: Oral isotretinoin (drug of choice); ampicillin for Type I

13. Pyoderma Faciale (Rosacea Fulminans)

• Sudden onset of large, coalescing nodules and cysts predominantly on the central face in adult women (20–40 years)
• No prior acne history; no comedones
• Systemic features absent (unlike acne fulminans)
• Treatment: Oral isotretinoin ± short course of prednisone initially

PART B: TREATMENT OF SEVERE ACNE VULGARIS

Definition of Severe Acne

• Nodular acne: ≥5 nodules (>5 mm)
• Nodulocystic acne with extensive involvement
• Acne conglobata and acne fulminans
• Acne causing severe psychosocial distress or scarring

1. ISOTRETINOIN (Oral Retinoid — Cornerstone of Severe Acne Treatment)

• ↓ Sebum production (↓ sebaceous gland size and activity — most potent sebosuppressant known)
• ↓ Follicular hyperkeratinization and comedogenesis
• ↓ C. acnes colonization (indirectly via hostile sebaceous environment)
• Anti-inflammatory effects

• Standard: 0.5–1.0 mg/kg/day in divided doses (with meals)
• Cumulative dose of 120–150 mg/kg required for optimal, lasting remission
• Lower starting dose (0.1–0.25 mg/kg/day) recommended for:
  • Very severe disease, acne conglobata, acne fulminans (to prevent initial flare)
  • Patients prone to scarring

2. MONITORING AND SIDE EFFECTS

• LFTs, fasting lipid profile, pregnancy test (in females)
• Repeat at 4 weeks, then every 2–3 months

3. ORAL ANTIBIOTICS (For Initial Disease Control Concurrent with Isotretinoin or Prior)

• Doxycycline: 50–100 mg BD (preferred — fewer resistance issues)
• Minocycline: 50–100 mg BD (higher risk of pigmentation, lupus-like reaction)
• Sarecycline: Narrow-spectrum tetracycline, once daily (lower GI and photosensitivity side effects)

4. HORMONAL THERAPY (Women Only)

• Block ovarian and adrenal androgen production
• Equivalent to oral antibiotics in reducing lesion counts at 6 months
• FDA-approved pills: Norgestimate + ethinyl estradiol (Ortho Tri-Cyclen); Norethindrone + ethinyl estradiol (Estrostep); Drospirenone + ethinyl estradiol (Yaz)
• Preferred progestins: Drospirenone or norgestimate (low androgenic activity)

• Androgen receptor blocker; inhibits 5α-reductase
• Dose: 50–150 mg/day
• Especially effective for adult female acne with mandibular distribution
• Side effects: Irregular menses, hyperkalemia, breast tenderness

• Potent antiandrogen; combined with ethinyl estradiol
• Highly effective for women with signs of hyperandrogenism

5. SYSTEMIC CORTICOSTEROIDS

• Acne fulminans: Prednisone 0.5–1 mg/kg/day for 2–4 weeks as monotherapy first, then introduce low-dose isotretinoin (0.1 mg/kg/day); taper steroids over 1–2 months
• Acne conglobata (acute): Short course before isotretinoin
• Pre-emptive cover in patients with macrocomedones or high risk of isotretinoin-induced flare
• Intralesional triamcinolone acetonide (2.5–5 mg/mL) for large nodules

6. TOPICAL THERAPY (Adjunctive)

• Topical retinoids (tretinoin 0.025–0.1%, adapalene 0.1–0.3%, tazarotene): Address comedonal component; continue after antibiotic course completed
• Benzoyl peroxide (BPO) 2.5–10%: Bactericidal, reduces antibiotic resistance; essential in combination regimens
• Topical clindamycin/erythromycin: Always combined with BPO to prevent resistance
• Topical dapsone 5–7.5%: Anti-inflammatory; favored in adult women
• Ivermectin 1% cream / Azelaic acid 15–20%: Adjunctive anti-inflammatory

7. NEWER/EMERGING THERAPIES

• Trifarotene 0.005% cream — 4th-generation retinoic acid receptor-γ (RARγ) agonist; approved for truncal acne
• Clascoterone (Winlevi) 1% cream — First topical antiandrogen; blocks androgen receptors in skin; FDA-approved 2020
• Sarecycline — Narrow-spectrum tetracycline reducing gut microbiome disruption
• Biologics: TNF inhibitors, IL-1 antagonists (anakinra) — second-line in acne fulminans refractory to standard therapy
• Dapsone oral — Particularly beneficial in acne fulminans with associated erythema nodosum

8. PHYSICAL / PROCEDURAL TREATMENTS

• Comedone extraction / acne surgery: Intralesional corticosteroids, comedone extraction
• Chemical peels: Salicylic acid, glycolic acid, Jessner's solution — comedolytic, anti-inflammatory
• Photodynamic therapy (PDT): ALA/MAL + visible light; reduces sebum, C. acnes, inflammation
• Laser and light therapies: Blue light (415 nm) — bactericidal; pulsed dye laser for post-inflammatory erythema
• Scar management: Fractionated laser resurfacing, dermabrasion, subcision, punch grafting for ice-pick scars, fillers for rolling scars, excision for sinus tracts

Summary Algorithm for Severe Acne

Severe nodular/nodulocystic acne
         ↓
Isotretinoin 0.5–1 mg/kg/day (cumulative 120–150 mg/kg)
  + Topical retinoid + BPO (adjunct)
  + Hormonal therapy if female
         ↓
Acne conglobata / fulminans
  → Start prednisone 0.5–1 mg/kg/day × 2–4 weeks FIRST
  → Add low-dose isotretinoin 0.1 mg/kg/day after 2–4 weeks
  → Taper steroids; slowly escalate isotretinoin
         ↓
Monitoring: LFT, lipids, CBC, pregnancy test q4–8 weeks